{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:31:53Z","timestamp":1793971913334,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108785","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:34:55Z","timestamp":1759336495000},"page":"108785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparative analysis of the tumor immune microenvironment between thymoma and thymic carcinoma"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5389-4631","authenticated-orcid":false,"given":"Shoko Sonobe","family":"Shimamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4692","authenticated-orcid":false,"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-2848","authenticated-orcid":false,"given":"Daiki","family":"Ikarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-0708","authenticated-orcid":false,"given":"Mariko","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-6364","authenticated-orcid":false,"given":"Kazuya","family":"Takamochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-8298","authenticated-orcid":false,"given":"Shigehisa","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108785_b0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108785_b0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JTO.0000000000000154","article-title":"ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting","volume":"9","author":"Marx","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0015","unstructured":"T.W.C.o.T.E. Board, The WHO classification of Tumours 5th ed. Thoracic Tumours., The WHO Classification of Tumours Editional Board ed., WORLD HEALT ORGANIZATION, Lyon, France, 2021."},{"key":"10.1016\/j.lungcan.2025.108785_b0020","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1097\/JTO.0000000000000300","article-title":"Paraneoplastic disorders in thymoma patients","volume":"9","author":"Evoli","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0025","doi-asserted-by":"crossref","unstructured":"M. Hirokawa, K. Sawada, N. Fujishima, S. Nakao, A. Urabe, K. Dan, S. Fujisawa, Y. Yonemura, F. Kawano, M. Omine, K. Ozawa, P.C.S. Group, Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group, Haematologica. 93 (2008) 27-33, https:\/\/doi.org\/10.3324\/haematol.11655.","DOI":"10.3324\/haematol.11655"},{"key":"10.1016\/j.lungcan.2025.108785_b0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00277-003-0635-z","article-title":"B-cell lymphopenia and hypogammaglobulinemia in thymoma patients","volume":"82","author":"Montella","year":"2003","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lungcan.2025.108785_b0035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1152\/physrev.1980.60.3.756","article-title":"Immunology of acetylcholine receptors in relation to myasthenia gravis","volume":"60","author":"Vincent","year":"1980","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lungcan.2025.108785_b0040","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2025.108785_b0045","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0050","doi-asserted-by":"crossref","unstructured":"K. Kondo, Y. Monden, Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan, Ann. Thorac. Surg. 76 (2003) 878-884; discussion 884-875, https:\/\/doi.org\/10.1016\/s0003-4975(03)00555-1.","DOI":"10.1016\/S0003-4975(03)00555-1"},{"issue":"101","key":"10.1016\/j.lungcan.2025.108785_b0055","first-page":"e101","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"95\u2013100","author":"Ahmad","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2025.108785_b0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/ejcts\/ezt649","article-title":"Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database","volume":"46","author":"Ruffini","year":"2014","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2025.108785_b0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","article-title":"Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database","volume":"9","author":"Ruffini","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejcts.2004.04.041","article-title":"Long-term survival and prognostic factors in thymic epithelial tumours","volume":"26","author":"Rea","year":"2004","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2025.108785_b0075","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.athoracsur.2016.12.042","article-title":"A meta-analysis of postoperative radiotherapy for thymic carcinoma","volume":"103","author":"Hamaji","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2025.108785_b0080","doi-asserted-by":"crossref","unstructured":"A. Fornasiero, O. Daniele, C. Ghiotto, M. Piazza, L. Fiore-Donati, F. Calabr\u00f3, F. Rea, M.V. Fiorentino, Chemotherapy for invasive thymoma. A 13-year experience, Cancer. 68 (1991) 30-33, https:\/\/doi.org\/10.1002\/1097-0142(19910701)68:1<30::aid-cncr2820680106>3.0.co;2-4.","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4"},{"key":"10.1016\/j.lungcan.2025.108785_b0085","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0090","first-page":"1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial","volume":"12","author":"Loehrer","year":"1994","journal-title":"The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology."},{"key":"10.1016\/j.lungcan.2025.108785_b0095","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: Report of a Japan Clinical Oncology Group trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108785_b0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0110","unstructured":"D.E. David, J.R. Gregory, et al., NCCN Clinical Practice Guidelines in Oncology Thymomas and Thymic Carcinomas Version 2.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thymic.pdf, 2022 (2022)."},{"key":"10.1016\/j.lungcan.2025.108785_b0115","doi-asserted-by":"crossref","first-page":"S1509","DOI":"10.21037\/jtd.2017.10.157","article-title":"Thymic tumors and immune checkpoint inhibitors","volume":"10","author":"Yokoyama","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2025.108785_b0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0125","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108785_b0135","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2025.108785_b0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108785_b0145","doi-asserted-by":"crossref","unstructured":"L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A. Aparicio, S. Behjati, A.V. Biankin, G.R. Bignell, N. Bolli, A. Borg, A.L. B\u00f8rresen-Dale, S. Boyault, B. Burkhardt, A.P. Butler, C. Caldas, H.R. Davies, C. Desmedt, R. Eils, J.E. Eyfj\u00f6rd, J.A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinski, N. J\u00e4ger, D.T. Jones, D. Jones, S. Knappskog, M. Kool, S.R. Lakhani, C. L\u00f3pez-Ot\u00edn, S. Martin, N.C. Munshi, H. Nakamura, P.A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J.V. Pearson, X.S. Puente, K. Raine, M. Ramakrishna, A.L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T.N. Schumacher, P.N. Span, J.W. Teague, Y. Totoki, A.N. Tutt, R. Vald\u00e9s-Mas, M.M. van Buuren, L. van 't Veer, A. Vincent-Salomon, N. Waddell, L.R. Yates, J. Zucman-Rossi, P.A. Futreal, U. McDermott, P. Lichter, M. Meyerson, S.M. Grimmond, R. Siebert, E. Campo, T. Shibata, S.M. Pfister, P.J. Campbell, M.R. Stratton, A.P.C.G. Initiative, I.B.C. Consortium, I.M.-S. Consortium, I. PedBrain, Signatures of mutational processes in human cancer, Nature. 500 (2013) 415-421, https:\/\/doi.org\/10.1038\/nature12477.","DOI":"10.1038\/nature12477"},{"key":"10.1016\/j.lungcan.2025.108785_b0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2025.108785_b0155","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108785_b0160","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.lungcan.2025.108785_b0165","first-page":"611","article-title":"Expression of CD20 in thymomas and its clinical implication","volume":"39","author":"Du","year":"2010","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.lungcan.2025.108785_b0170","series-title":"classification of tumours of lung, pleura, thymus and heart","author":"Travis","year":"2015"},{"key":"10.1016\/j.lungcan.2025.108785_b0175","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Regulatory T cells in tumor immunity","volume":"127","author":"Nishikawa","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108785_b0180","doi-asserted-by":"crossref","unstructured":"C. Badoual, S. Hans, J. Rodriguez, S. Peyrard, C. Klein, N.l.H. Agueznay, V. Mosseri, O. Laccourreye, P. Bruneval, W.H. Fridman, D.F. Brasnu, E. Tartour, Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers, Clinical cancer research : An Official Journal of the American Association for Cancer Research. 12 (2006) 465-472, https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1886.","DOI":"10.1158\/1078-0432.CCR-05-1886"},{"key":"10.1016\/j.lungcan.2025.108785_b0185","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","article-title":"Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer","volume":"27","author":"Salama","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108785_b0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.09.002","article-title":"Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma","volume":"125","author":"Wei","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108785_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239056","article-title":"Immunobiology of thymic epithelial tumors: implications for immunotherapy with immune checkpoint inhibitors","volume":"21","author":"Tateo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2025.108785_b0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2249.1998.00606.x","article-title":"Neoplastic thymic epithelial cells of human thymoma support T cell development from CD4-CD8- cells to CD4+CD8+ cells in vitro","volume":"112","author":"Inoue","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.lungcan.2025.108785_b0205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00000478-200101000-00012","article-title":"Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors","volume":"25","author":"Okumura","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2025.108785_b0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lungcan.2025.108785_b0215","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.lungcan.2025.108785_b0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.ai.2015.12.002","article-title":"Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers","volume":"130","author":"Becht","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.lungcan.2025.108785_b0225","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2025.108785_b0230","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2025.108785_b0235","first-page":"1341","article-title":"Impact of PD-L1, transforming growth factor-\u03b2 expression and tumor-infiltrating CD8, Thorac","volume":"9","author":"Duan","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108785_b0240","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/cas.14409","article-title":"CD20 tumor-infiltrating immune cells and CD204 M2 macrophage are associated with prognosis in thymic carcinoma","volume":"111","author":"Sato","year":"2020","journal-title":"Cancer Sci."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:45:53Z","timestamp":1762490753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"alternative-id":["S0169500225006774"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108785","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of the tumor immune microenvironment between thymoma and thymic carcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108785"}}